Treatment of obstructive airway diseases with roflumilast, a novel phosphodiesterase 4 inhibitor

References

• Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet364(9434), 613–620 (2004).
   PubMed Web of Science ®Google Scholar
• Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am. J. Clin. Nutr.82(1), 53–59 (2005).
   PubMed Web of Science ®Google Scholar
• Hogg JC. Why does airway inflammation persist after the smoking stops? Thorax61(2), 96–97 (2006).
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med.350(26), 2645–2653 (2004).
   PubMed Web of Science ®Google Scholar
• Holgate ST. Biomarkers of asthma. Lancet351(9112), 1300–1301 (1998).
   PubMedGoogle Scholar
• Howarth PH, Bradding P, Montefort S et al. Mucosal inflammation and asthma. Am. J. Respir. Crit. Care Med.150(5 Pt 2), S18–S22 (1994).
   Google Scholar
• Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med.170(8), 836–844 (2004).
   PubMed Web of Science ®Google Scholar
• Pauwels R. Global initiative for chronic Obstructive Lung Diseases (GOLD): time to act. Eur. Respir. J.18(6), 901–902 (2001).
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Theophylline: new perspectives for an old drug. Am. J. Respir. Crit. Care Med.167(6), 813–818 (2003).
   PubMed Web of Science ®Google Scholar
• Essayan DM. Cyclic nucleotide phosphodiesterases. J. Allergy Clin. Immunol.108(5), 671–680 (2001).
   PubMed Web of Science ®Google Scholar
• Houslay MD. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol.69, 249–315 (2001).
   PubMed Web of Science ®Google Scholar
• Omori K, Kotera J. Overview of PDEs and their regulation. Circ. Res.100(3), 309–327 (2007).
   PubMed Web of Science ®Google Scholar
• Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med.325(21), 1468–1475 (1991).
   PubMed Web of Science ®Google Scholar
• Lewis GD, Semigran MJ. Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. Curr. Heart Fail. Rep.1(4), 183–189 (2004).
   PubMedGoogle Scholar
• Salonia A, Rigatti P, Montorsi F. Sildenafil in erectile dysfunction: a critical review. Curr. Med. Res. Opin.19(4), 241–262 (2003).
   PubMed Web of Science ®Google Scholar
• David M, Zech K, Seiberling A. Roflumilast, a novel, oral, selective PDE4 inhibitor, shows high absolute bioavailablilty. J. Allergy Clin. Immunol.113, P780 (2004).
   Google Scholar
• Bethke T, Hartmann M, Zech K. No dose adjustment of roflumilast in patients with severe renal impairment. Am. J. Respir. Crit. Care Med.165, A594 (2002).
   Google Scholar
• Bethke TD, Giessmann T, Westphal K et al. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. Int. J. Clin. Pharmacol. Ther.44(11), 572–579 (2006).
   PubMed Web of Science ®Google Scholar
• Hauns B, Hermann R, Hunnemeyer A et al. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. J. Clin. Pharmacol.46(10), 1146–1153 (2006).
   PubMed Web of Science ®Google Scholar
• Nassr N, Lahu G, von Richter O et al. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects. Br. J. Clin. Pharmacol.63(3), 365–370 (2007).
   PubMed Web of Science ®Google Scholar
• Lagente V, Pruniaux MP, Junien JL, Moodley I. Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors. Am. J. Respir. Crit. Care Med.151(6), 1720–1724 (1995).
   PubMedGoogle Scholar
• Rabe KF, Bateman ED, O’Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet366(9485), 563–571 (2005).
   PubMed Web of Science ®Google Scholar
• Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther.297(1), 267–279 (2001).
   PubMed Web of Science ®Google Scholar
• Mata M, Sarria B, Buenestado A, Cortijo J, Cerda M, Morcillo EJ. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax60(2), 144–152 (2005).
   PubMed Web of Science ®Google Scholar
• Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J. Pharmacol. Exp. Ther.315(3), 1188–1195 (2005).
   PubMed Web of Science ®Google Scholar
• Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J. Pharmacol. Exp. Ther.297(1), 280–290 (2001).
   PubMed Web of Science ®Google Scholar
• Bosswell-Smith V, Spina D, Page C. Regulation by selective PDE4 isoenzyme inhibitors of NANC contraction in guinea pig isolated main bronchus. Am. J. Respir. Crit. Care Med.168, A180 (2004).
   Google Scholar
• Burgess JK, Oliver BG, Poniris MH et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J. Allergy Clin. Immunol.118(3), 649–657 (2006).
   PubMed Web of Science ®Google Scholar
• Kumar RK, Herbert C, Thomas PS et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J. Pharmacol. Exp. Ther.307(1), 349–355 (2003).
   PubMed Web of Science ®Google Scholar
• Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am. J. Respir. Crit. Care Med.172(7), 848–853 (2005).
   PubMed Web of Science ®Google Scholar
• Wollin L, Marx D, Wohlsen A, Beume R. Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs. J. Asthma42(10), 873–878 (2005).
   PubMed Web of Science ®Google Scholar
• Grootendorst D, Gauw S, Sterk P. Treatment with PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Proc. Am. Thorac. Soc.2, A543 (2005).
   Google Scholar
• Izquierdo J, Bateman E, Villasante C, Schmidt-Wirlitsch C, Bredenbrocker D, Wurst W. Long term efficacy and safety over one year of once daily roflumilast in asthma. Am. J. Respir. Crit. Care Med.167, A765 (2003).
   Google Scholar
• Nell H, Louw C, Leichtl S, Rathgeb F, Bardin P. Acute anti-inflammatory effect of the novel PDE4 inhibitor roflumilast on allergen challenge after a single dose. Am. J. Respir. Crit. Care Med.161, A200 (2000).
   PubMed Web of Science ®Google Scholar
• van Schalkwyk E, Strydom K, Williams Z et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol.116(2), 292–298 (2005).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Aubier M, Sastre J et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy61(1), 72–78 (2006).
   PubMed Web of Science ®Google Scholar
• Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br. Med. J.323(7307), 253–256 (2001).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Izquierdo JL, Harnest U et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann. Allergy Asthma Immunol.96(5), 679–686 (2006).
   PubMed Web of Science ®Google Scholar
• Timmer W, Leclerc V, Birraux G et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-α ex vivo. J. Clin. Pharmacol.42(3), 297–303 (2002).
   PubMed Web of Science ®Google Scholar
• Schmidt BM, Kusma M, Feuring M et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J. Allergy Clin. Immunol.108(4), 530–536 (2001).
   PubMed Web of Science ®Google Scholar
• Losco PE, Evans EW, Barat SA et al. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol. Pathol.32(3), 295–308 (2004).
   Google Scholar
• McCluskie K, Klein U, Linnevers C et al. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo. J. Pharmacol. Exp. Ther.319(1), 468–476 (2006).
   PubMedGoogle Scholar